Germany · Delayed Price · Currency is EUR Bio-Gate AG Statistics
Total Valuation
Bio-Gate AG has a market cap or net worth of EUR 4.57 million. The enterprise value is 4.56 million.
| Market Cap | 4.57M |
| Enterprise Value | 4.56M |
Important Dates
The next estimated earnings date is Thursday, December 10, 2026.
| Earnings Date | Dec 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Bio-Gate AG has 2.04 million shares outstanding.
| Current Share Class | 2.04M |
| Shares Outstanding | 2.04M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +20.55% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.66 |
| PB Ratio | 7.46 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.66 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.50, with zero debt.
| Current Ratio | 4.50 |
| Quick Ratio | 0.97 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.46 |
Financial Efficiency
Return on equity (ROE) is -174.61% and return on invested capital (ROIC) is -77.45%.
| Return on Equity (ROE) | -174.61% |
| Return on Assets (ROA) | -18.70% |
| Return on Invested Capital (ROIC) | -77.45% |
| Return on Capital Employed (ROCE) | -34.72% |
| Weighted Average Cost of Capital (WACC) | 4.73% |
| Revenue Per Employee | 134,901 |
| Profits Per Employee | -25,823 |
| Employee Count | 51 |
| Asset Turnover | 1.69 |
| Inventory Turnover | 1.99 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.00% in the last 52 weeks. The beta is 0.09, so Bio-Gate AG's price volatility has been lower than the market average.
| Beta (5Y) | 0.09 |
| 52-Week Price Change | -44.00% |
| 50-Day Moving Average | 2.54 |
| 200-Day Moving Average | 2.94 |
| Relative Strength Index (RSI) | 35.95 |
| Average Volume (20 Days) | 316 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bio-Gate AG had revenue of EUR 6.88 million and -1.32 million in losses.
| Revenue | 6.88M |
| Gross Profit | 3.85M |
| Operating Income | -1.22M |
| Pretax Income | -1.33M |
| Net Income | -1.32M |
| EBITDA | -984,516 |
| EBIT | -1.22M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 78,418 in cash and no debt, with a net cash position of 78,418 or 0.04 per share.
| Cash & Cash Equivalents | 78,418 |
| Total Debt | n/a |
| Net Cash | 78,418 |
| Net Cash Per Share | 0.04 |
| Equity (Book Value) | 612,014 |
| Book Value Per Share | n/a |
| Working Capital | 1.57M |
Cash Flow
In the last 12 months, operating cash flow was -1.06 million and capital expenditures -3,000, giving a free cash flow of -1.06 million.
| Operating Cash Flow | -1.06M |
| Capital Expenditures | -3,000 |
| Depreciation & Amortization | 232,000 |
| Net Borrowing | 410,000 |
| Free Cash Flow | -1.06M |
| FCF Per Share | -0.52 |
Margins
Gross margin is 56.00%, with operating and profit margins of -17.68% and -19.14%.
| Gross Margin | 56.00% |
| Operating Margin | -17.68% |
| Pretax Margin | -19.40% |
| Profit Margin | -19.14% |
| EBITDA Margin | -14.31% |
| EBIT Margin | -17.68% |
| FCF Margin | n/a |
Dividends & Yields
Bio-Gate AG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -28.84% |
| FCF Yield | -23.19% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Bio-Gate AG is 10.48, which is 367.86% higher than the current price. The consensus rating is "Buy".
| Price Target | 10.48 |
| Price Target Difference | 367.86% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 3.81% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on July 28, 2026. It was a reverse split with a ratio of 0.2.
| Last Split Date | Jul 28, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |